https://www.wsj.com/articles/amc-networks-ceo-christina-spade-steps-down-after-less-than-three-months-11669729033?st=e8t2l8drbgsfli3
AstraZeneca And Merck Announced Results From The Final Analysis Of Overall Survival From Phase 3 Propel Trial Of Lynparza Plus Abiraterone And Prednisone Or Prednisolone (Abi/Pred), Compared To Placebo Plus Abi/Pred. Did Not Reach Statistical Significa…
Median OS was 42.1 months for the LYNPARZA plus abi/pred arm versus 34.7 months for the placebo plus abi/pred arm, representing a 7.4-month absolute difference in median OS versus a standard of care